Full Press Release Details
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders.
RAPP
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
Key Takeaway: CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
Price reaction · baseline $16.69 (2025-01-08 close) · hit after-hours · clean, no other RAPP news in the window
day 0 close
-11.3%
day 1
-16.3%
day 3 · peak
-20.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+91%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
RAP-219
Phase 3 · Focal Seizure